Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies. This story was originally published on BioPharma Dive. To receive ...

The Flagship Pioneering spinout uses permanent bonds to target shallow pockets, drastically expanding the druggable universe for small molecules.

Discover how researchers are overcoming the limitations of the undruggable target in drug discovery using novel approaches ...

The first patient dosing in the Phase 1/2 trial represents a crucial step in assessing NEO-811's efficacy and safety. The Phase 1/2 NEO-811-101 trial is a first-in-human, open-label study designed to ...

Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...

In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously "undruggable" cancer-driving ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

Researchers developed nanotechnology that selectively binds and degrades abnormal proteins. The technology shows promise for ...

Designing drugs is a bit like playing with Polly Pocket. The vintage toy is a plastic clam shell that contains a multi-bedroom house, a skating rink, a disco dance floor, and other fun scenarios. Kids ...

Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs — a ...